Soleno Therapeutics Announces Proposed Public Offering of Common Stock

Rhea-AI Summary

Soleno Therapeutics, Inc. (Nasdaq: SLNO) announced plans for an underwritten public offering of its common stock, with the potential for underwriters to purchase an additional 15% of the shares. The offering is contingent on market conditions and details regarding size and terms are not yet confirmed. Guggenheim Securities, LLC will act as the sole book-running manager for the offering. The securities are being registered with the SEC, and the company is focused on developing treatments for rare diseases, including its lead candidate for Prader-Willi Syndrome.

Positive

• The offering aims to raise funds for the development of novel therapeutics.
• Potential for underwriters to purchase an additional 15% indicates market interest.

Negative

• The offering could lead to shareholder dilution due to the issuance of new shares.
• Market conditions may delay the offering, introducing uncertainty.

REDWOOD CITY, Calif., June 23, 2020 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Nasdaq: SLNO), (“Soleno” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today that it intends to offer and sell shares of its common stock in an underwritten public offering.  In addition, Soleno intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Guggenheim Securities, LLC is acting as the sole book-running manager for the offering. 

The securities described above are being offered by Soleno pursuant to a registration statement previously filed with, and declared effective by, the Securities and Exchange Commission (the “SEC”). A preliminary prospectus supplement and accompanying prospectus relating to this offering will be filed with the SEC. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. When available, copies of the preliminary prospectus supplement and the accompanying prospectus relating to this offering may be obtained from Guggenheim Securities, LLC Attention: Equity Syndicate Department, 330 Madison Avenue, New York, NY 10017 or by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com.  Electronic copies of the preliminary prospectus supplement and accompanying prospectus will also be available on the website of the SEC at www.sec.gov.

About Soleno Therapeutics, Inc.

Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company’s lead candidate, Diazoxide Choline Controlled-Release (DCCR) tablets, a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is currently being evaluated in a Phase III clinical development program.  

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding the Company’s expectations on the completion, timing and size of the proposed public offering and the anticipated use of proceeds therefrom. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other similar expressions. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, including the risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the proposed public offering, as well as risks and uncertainties inherent in Soleno’s business, including those described in the company's prior press releases and in the periodic reports it files with the SEC. The events and circumstances reflected in the company's forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, the company does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Corporate Contact:

Brian Ritchie
LifeSci Advisors, LLC
212-915-2578 

FAQ

What is the purpose of Soleno Therapeutics' public offering on June 23, 2020?

The public offering is intended to raise capital for the development of novel therapeutics.

How much common stock is Soleno Therapeutics offering?

The exact amount of common stock being offered has not been specified and is subject to market conditions.

Who is managing Soleno Therapeutics’ public offering?

Guggenheim Securities, LLC is the sole book-running manager for the offering.

What is the ticker symbol for Soleno Therapeutics?

The ticker symbol for Soleno Therapeutics is SLNO.

Will there be any shareholder dilution from the offering?

Yes, the public offering could result in shareholder dilution due to the issuance of new shares.